Hyperbaric oxygen reduces neuronal death and improves neurological outcome after canine cardiac arrest

George Washington University, Washington, Washington, D.C., United States
Stroke (Impact Factor: 6.02). 06/2003; 34(5):1311-6. DOI: 10.1161/01.STR.0000066868.95807.91
Source: PubMed

ABSTRACT Studies suggest that hyperbaric oxygen (HBO) is neuroprotective after experimental cerebral ischemia, but the mechanism is unknown. This study tested the hypotheses that postischemic HBO affords clinical and histopathological neuroprotection after experimental cardiac arrest and resuscitation (A/R) and that this neuroprotection results from improved cerebral oxygen metabolism after A/R.
Anesthetized adult female beagles underwent A/R and randomization to HBO (2.7-atm absolute [ATA] for 60 minutes, 1 hour after A/R) or control (Po2=80 to 100 mm Hg; 1 ATA). Animals underwent neurological deficit scoring (NDS) 23 hours after A/R. After euthanasia at 24 hours, neuronal death (necrotic and apoptotic) in representative animals was determined stereologically in hippocampus and cerebral neocortex. In experiment 2, arterial and sagittal sinus oxygenation and cerebral blood flow (CBF) were measured. Cerebral oxygen extraction ratio (ERc), oxygen delivery (Do2c), and metabolic rate for oxygen (CMRo2) were calculated (baseline and 2, 30, 60, 120, 180, 240, 300, and 360 minutes after restoration of spontaneous circulation).
NDS improved after A/R in HBO animals (HBO, 35+/-14; controls, 54+/-15; P=0.028). Histopathological examination revealed significantly fewer dying neurons in HBO animals; the magnitude of neuronal injury correlated well with NDS. HBO corrected elevations in ERc (peak, 60+/-14% for controls, 26+/-4% for HBO) but did not increase Do2c or CMRo2, which decreased approximately 50% after A/R in both groups.
HBO inhibits neuronal death and improves neurological outcome after A/R; the mechanism of HBO neuroprotection is not due to stimulation of oxidative cerebral energy metabolism.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Love "The cost of Traumatic Brain Injuries (TBI) is approximately $56 billion, and more than 5 million Americans alive today have had TBI related injury resulting in a permanent need for help in performing daily activities. Survivors of TBI are often left with significant cognitive, behavioral, and communicative disabilities, and some patients develop long-term medical complications, such as epilepsy." (National Institutes of Neurological Disorders and Stroke, NIH, 2010) INTRODUCTION Traumatic Brain Injuries (TBI) are becoming one of the leading causes of death and life-long disabilities in infants, adolescents, adults and senior citizens (1) . Consequently, there is an increasing concern among parents and health care providers regarding the prevalence of brain injuries in commonly practiced sports; car related accidents, worker injuries as well as increasing number of brain-injured soldiers returning from war theaters. Approximately 1.7 million Americans will experience a brain injury annually, with ~80% of those patients diagnosed with mild-to-moderate TBI (1) . Limited medical and technological tools to address this urgent concern have created a strong need to develop new approaches to treat TBI sufferers. Hyperbaric Oxygen Therapy (HBOT) has been used for more than a 100 years to increase oxygen intake in damaged or oxygen-starved tissues. By increasing atmospheric pressure around the damaged tissue and applying 100% oxygen, the total amount of oxygen in the blood and organs increases, ensuring that all cells are supplied with this life sustaining gas. Evidence of the benefits of HBOT in the treatment of Traumatic Brain Injury has been accumulating for the last 30 years with encouraging results. Recent clinical reports and animal studies support the idea that patients with mild-to-moderate brain injury can greatly accelerate their recovery and reverse damage with HBOT. Currently medications focus on controlling brain injury symptoms rather than brain recovery. HBOT has shown positive benefits for mild-to-moderate TBI now and can reverse damage that is untreatable with drugs.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Studies have shown the detrimental effect of hyperoxia in animals with return of spontaneous circulation (ROSC) after cardiac arrest. To maximize the value of existing clinical studies, we performed the systemic review and meta-analysis of human observational studies to examine the effect of hyperoxia on outcomes of post-ROSC patients. Methods: We searched PubMed and Embase from the inception to October 2013. We selected adult observational studies that compared different levels of partial pressure of arterial oxygen (PaO2) in post-ROSC patients with mortality or neurological status at hospital discharge as outcome. Studies comparing hypoxia with normoxia only were excluded. Results: Fourteen studies were identified from 2982 references. Odds ratio (OR) was used as effect estimate. OR was reconstructed if not provided in original articles. Hyperoxia was defined as a PaO2 >300 mmHg. Meta-analysis indicated that hyperoxia appeared to be correlated with increased in-hospital mortality (OR, 1.40; 95% CI, 1.02-1.93; I-2, 69.27%; 8 studies) but not worsened neurological outcome (OR, 1.62; 95% CI, 0.87-3.02; I-2, 55.61%; 2 studies). However, the results were inconsistent in subgroup and sensitivity analyses. Conclusions: Hyperoxia appears to be correlated with increased in-hospital mortality of post-ROSC patients. This result should be interpreted cautiously because of the significant heterogeneity and limited number of studies analyzed. However, because exposure to hyperoxia had no obvious benefits, clinicians should monitor PaO2 closely and titrate oxygen administration cautiously.
    Resuscitation 05/2014; 85(9). DOI:10.1016/j.resuscitation.2014.05.021 · 3.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neurocognitive deficits remain a significant source of morbidity in survivors of cardiac arrest. We conducted a literature review of treatment protocols designed to evaluate neurologic outcome and survival following global cerebral ischemia associated with cardiac arrest. The search was limited to investigational therapies that were implemented either during cardiopulmonary resuscitation or after return of spontaneous circulation in studies that included assessment of impact on neurologic outcome. Given that complex pathophysiology underlies global brain hypoxic ischemia following cardiac arrest, neuroprotective strategies targeting multiple stages of neuropathologic cascades should promise to improve survival and neurologic outcomes in cardiac arrest victims. In Part II of this review, we discuss several approaches that can provide comprehensive protection against global brain injury associated with cardiac arrest, by modulating multiple targets of neuropathologic cascades. Pharmaceutical approaches include adenosine and growth factors/hormones including brain-derived neurotrophic factor, insulin-like growth factor-1 and glycine-proline-glutamate, granulocyte colony stimulating factor and estrogen. Preclinical studies of these showed some benefit but were inconclusive in models of global brain injury involving systemic ischemia. Several medical gases that can mediate neuroprotection have been evaluated in experimental settings. These include hydrogen sulfide, hyperbaric oxygen and molecular hydrogen. Hyperbaric oxygen and molecular hydrogen showed promising results; however, further investigation is required prior to clinical application of these agents in cardiac arrest patients.